Cargando…
Use of Ultrasound and Ki–67 Proliferation Index to Predict Breast Cancer Tumor Response to Neoadjuvant Endocrine Therapy
Background: Prediction of tumor shrinkage and pattern of treatment response following neoadjuvant endocrine therapy (NET) for estrogen receptor positive (ER+), Her2 negative (Her2–) breast cancers have had limited assessment. We examined if ultrasound (US) and Ki–67 could predict the pathologic resp...
Autores principales: | Liebscher, Sean C., Kilgore, Lyndsey J., Winblad, Onalisa, Gloyeske, Nika, Larson, Kelsey, Balanoff, Christa, Nye, Lauren, O’Dea, Anne, Sharma, Priyanka, Kimler, Bruce, Khan, Qamar, Wagner, Jamie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913996/ https://www.ncbi.nlm.nih.gov/pubmed/36766992 http://dx.doi.org/10.3390/healthcare11030417 |
Ejemplares similares
-
Mammographic density does not correlate with Ki-67 expression or cytomorphology in benign breast cells obtained by random periareolar fine needle aspiration from women at high risk for breast cancer
por: Khan, Qamar J, et al.
Publicado: (2007) -
The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer
por: Zhang, Ailin, et al.
Publicado: (2021) -
Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer
por: Goncalves, Rodrigo, et al.
Publicado: (2017) -
Ki67 and the apparent diffusion coefficient in postoperative prostate cancer with endocrine therapy
por: He, Jun, et al.
Publicado: (2023) -
Ki-67 as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
por: Kim, Kwan Il, et al.
Publicado: (2014)